THE 2-MINUTE RULE FOR ABBV-744 IN THE TREATMENT OF DRUG-RESISTANT CANCERS

The current work examined the potential of using ARV-825 and ABBV-744 to improve the effectiveness of tamoxifen or fulvestrant furthermore palbociclib. ARV-825 was effective in both equally p53 wild-type (WT) breast tumor cells As well as in cells missing functional p53 either on your own or in combination with tamoxifen, even though the effectiven